目的和方法：高增殖潜能集落形成细胞（ＨＰＰＣＦＣ）是表达ＣＤ３４＋ＤＲＬｉｎ－的最早期造血祖细胞之一，它在体外的增殖分化能力可反映造血干细胞的某些特征。结果：本文研究了人正常骨髓ＣＤ３４＋造血细胞在体外扩增和形成ＨＰＰＣＦＣ的能力。利用ＣＩＭＳ１００免疫磁性分离术首先获得＞９０％的ＣＤ３４＋造血细胞以富集ＨＰＰＣＦＣ。在含有Ｅｐｏ＋ＧＭＣＳＦ＋ＩＬ３＋ＩＬ６＋ＳＣＦ（简ＥＧＩＩＳ）的无基质液培条件下，ＣＤ３４＋造血细胞在四周内可持续产生单个核细胞和ＨＰＰＣＦＣ，并使其总量最高可达１７７０倍和８倍，以第２和３周为最佳时期，但不同个体ＣＤ３４＋造血细胞的这种能力差别较大。结论：高度纯化的人骨髓ＣＤ３４＋造血细胞能够在含有最佳组合造血生长因子的无基质液培条件下持续扩增，为临床应用提供了重要依据。 PURPOSE AND METHODS: HPCCFC, one of the earliest hematopoietic progenitor cells expressing CD34 + DRLin, has the ability to proliferate and differentiate in vitro and reflect some characteristics of hematopoietic stem cells. Results: In this paper, we studied the ability of human normal bone marrow CD34 + hematopoietic cells to proliferate and form HPP-FC in vitro. The use of CIMS 100 immunomagnetic separation obtained first> 90% of CD34 + hematopoietic cells to enrich HPP FCS. Under the medium-free culture medium containing Epo + GMCSF + IL3 + IL6 + SCF (Jane EGIIS), CD34 + hematopoietic cells can continuously produce mononuclear cells and HPPCFC within four weeks, and the total amount can reach 1770 times and 8 times, 2 and 3 weeks for the best period, but different individuals CD34 + hematopoietic cells of this ability vary greatly. CONCLUSION: The highly purified human bone marrow CD34 + hematopoietic cells can continue to proliferate in the matrix-free culture with the optimal combination of hematopoietic growth factors, providing an important basis for clinical application.